4basebio PLC
88Q
Company Profile
Business description
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
Contact
25 Norman Way
Over
CambridgeCB24 5QE
GBRT: +44 1223967943
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
110
Stocks News & Analysis
stocks
Chart of the Week: AI proving a threat to company moats
The latest insights on AI from our equity research team.
stocks
ASX coal miners will benefit from higher prices
Middle East conflict pushes coal prices higher.
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
We think Nvidia stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,690.70 | 21.10 | -0.24% |
| CAC 40 | 7,969.88 | 4.61 | -0.06% |
| DAX 40 | 23,502.25 | 228.67 | -0.96% |
| Dow JONES (US) | 46,225.15 | 768.11 | -1.63% |
| FTSE 100 | 10,305.29 | 98.31 | -0.94% |
| HKSE | 25,491.83 | 533.59 | -2.05% |
| NASDAQ | 22,152.42 | 327.11 | -1.46% |
| Nikkei 225 | 53,204.58 | 2,034.82 | -3.68% |
| NZX 50 Index | 13,051.61 | 263.99 | -1.98% |
| S&P 500 | 6,624.70 | 91.39 | -1.36% |
| S&P/ASX 200 | 8,497.80 | 7.60 | -0.09% |
| SSE Composite Index | 4,015.37 | 47.61 | -1.17% |